BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181009
DTEND;VALUE=DATE:20181011
DTSTAMP:20260515T022817
CREATED:20180717T104113Z
LAST-MODIFIED:20180717T104113Z
UID:16780-1539043200-1539215999@www.pharmajournalist.com
SUMMARY:Outsourcing in Clinical Trials DACH 2018
DESCRIPTION:We are pleased to announce that the OCT series is extending to Switzerland 2018 to bring innovative and solutions focused content to the DACH biopharmaceutical market. Spinning off from the flagship OCT Europe event this intimate audience of local players allows for focused\, lucrative learning and networking on site. \n \nThrough in-depth research conducted with local biopharma companies\, this event will deliver insight\, debate\, discussion\, presentation and opinion on high priority outsourcing\, operations and technology-based themes within the clinical trials space locally. \nKey Agenda Highlights 2018\n1) Building collaborations with external providers to guarantee the best delivery through innovation. (Gisele Tavares\, Procurement – Global Head Alliance Management and Internal Business Partner at Roche) \n2) Onstage Interview: Working to foster a reputation in clinical development to partner with large solution providers for trusted timelines and high-quality deliverables – (Dirk Weber\, Chief Medical Officer at Cellestia Biotech AG/Aurealis Pharma AG) \n3) Considerations in observational research – the importance of long-term partnerships – (Pamela Bacon\, Head of Medical Affairs Communications and Operations\, Worldwide Markets at Celgene)  \nWhy must you attend? \nOCTDACH brings recognised experts specifically in the DACH region to discuss\, collaborate and network with a variety of key service providers as well as other biopharmaceuticals from innovative and collaborative ideas to help overcome challenges. \nThis event will deliver insights\, debates\, discussions\, presentations and opinion on high priority outsourcing\, operations and technology-based themes within the clinical trial space locally. \nTo learn more about this event\, and to register online\, visit http://bit.ly/OCTDASH2018 \nContact: \nPhone – +44 (0) 207 936 6521\nEmail – brijesh.patel@arena-international.com
URL:https://www.pharmajournalist.com/event/outsourcing-in-clinical-trials-dach-2018/
LOCATION:Radisson Blu\, Zurich Airport\, Rondellstrasse\, 8058 Kloten\, CH-8058
ORGANIZER;CN="Arena International":MAILTO:brijesh.patel@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181010
DTEND;VALUE=DATE:20181012
DTSTAMP:20260515T022817
CREATED:20180507T072343Z
LAST-MODIFIED:20180507T090028Z
UID:15692-1539129600-1539302399@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy 2018
DESCRIPTION:SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018\, with an interactive pre-conference workshop on the 9th October. \n\nCell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing\, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery. \nThis year’s event will be led by scientists and clinicians researching\, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology\, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject\, including biomedical science principles\, molecular basis of disease\, current and developing technologies and clinical applications. \nThe conference will be inviting speakers from global pharmaceutical organisations\, leading biotech companies and internationally renowned academic institutions Expect over 16 presentations and case studies focused on the key aspects of GMP\, bioprocessing\, regulatory frameworks and new therapeutic developments in in the field of cell and gene. \nHear from our expert speaker panel\, bringing you interesting case studies and detailed presentations on new and industry relevant topics\, including: \n\nCell Therapy Research\nManufacturing Innovation\nGlobal Medical Affairs\nRegulatory Updates\nGMP and Quality Control\nCell and Tissue Therapies (CART therapies\, stem cells\, cord blood\, preclinical and clinical developments)\nRegenerative Medicine\nAdvanced Therapy Production\nGene Therapy Development\nClinical Platform Development\nManufacturing\nR&D of Cell and Gene Therapies\n\nCHAIR FOR 2018: \n\nPamela Tranter\, Head of Translational Research Group\, UCL\n\nKEY SPEAKERS INCLUDE: \n\nJanet Glassford\, Senior Quality Assessor (Biologicals)\, MHRA\nGiuseppe Ronzitti\, Cell and Gene Therapy Specialist\, Genethon\nKei Kishimoto\, Chief Scientific Officer\, Selecta Biosciences\nShailesh Gupta\, Senior Scientist\, AstraZeneca\nPeggy Sotiropoulou\, R&D Manager\, Research and Development\, Celyad\nJulie Kerby\, Head of Manufacturing Development\, Cell and Gene Therapy Catapult\nLior Raviv\, Vice President\, Development\, Pluristem\nDiego Aridgo\, R&D Rare Disease Unit Head\, Chiesi\nMehdi Gasmi\, Chief Science and Technology Officer\, Adverum Biotech\nEmanuela Cuomo\, Associate Director\, Discovery Sciences\, Cellular Biology Team\, AstraZeneca\nYen Choo\, Founder and Executive Chairman\, Plasticell\nIan McKay\, Innovation Lead Advanced Therapies\, Innovate UK\n\n2018 FEATURED HIGHLIGHTS: \n\nDiscuss the challenges of accessing patients with commercial ATMPs\nUnderstand the advantages of a risk-based approach to cell and gene therapy manufacturing\nHear the MHRA’s perspective of UK and EU regulatory affairs regarding ATMPs\nExplore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca\nGain insight into GMP Manufacture of plasmid DNA at the NHSBT\n\nView the full agenda online: www.cellandgeneconference.com/pj \nEARLY-BIRD RATES: \n\nREGISTER BY 31ST MAY AND SAVE £400\nREGISTER BY 29TH JUNE AND SAVE £300\nREGISTER BY 31ST AUGUST AND SAVE £200
URL:https://www.pharmajournalist.com/event/cell-gene-therapy-2018/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:psolanki@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181010
DTEND;VALUE=DATE:20181013
DTSTAMP:20260515T022817
CREATED:20180627T065536Z
LAST-MODIFIED:20180627T070348Z
UID:16489-1539129600-1539388799@www.pharmajournalist.com
SUMMARY:BioNetwork
DESCRIPTION:BioNetwork\n\nOctober 10 – 12\, 2018\nThe Ritz-Carlton\, Laguna Niguel\, CA. One\, Ritz Carlton Dr\, Dana Point\, CA 92629 \n\nBioNetwork is the essential deal-making event for business development executives in pharmaceutical and biotechnology. You’ll nurture strategic partnerships in our beautiful\, intimate venue. Pharma/Big Biotechs – register with code BIO18PHARMA and get 15% off your pass! \nTo learn more about this event\, and to register online\, visit bionetwork.wbresearch.com
URL:https://www.pharmajournalist.com/event/bionetwork/
LOCATION:The Ritz-Carlton\, Laguna Niguel\, One Ritz Carlton Drive\, Dana Point\, CA\, 92629\, United States
ORGANIZER;CN="Worldwide Business Research":MAILTO:bionetwork@wbresearch.com
END:VEVENT
END:VCALENDAR